ENERPAC TOOL GROUP CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ENERPAC TOOL GROUP CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $616.90M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $589.51M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $598.20M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $571.22M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $528.66M | Oct 20, 2023 |
| FY2021 | Aug 31, 2020 | $493.29M | Oct 25, 2021 |
| FY2020 | Aug 31, 2019 | $654.76M | Oct 26, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $616.90M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $589.51M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $598.20M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $571.22M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $528.66M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $493.29M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $654.76M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $641.30M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | $616.59M | Oct 29, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Aug 31, 2018 | $1.18B | Oct 29, 2018 |
| FY2018 | Aug 31, 2017 | $1.10B | Oct 29, 2018 |
| FY2018 | Aug 31, 2016 | $1.15B | Oct 29, 2018 |
| FY2017 | Aug 31, 2015 | $1.25B | Oct 26, 2017 |
| FY2014 | Aug 31, 2014 | $354.35M | Oct 27, 2014 |
| FY2014 | May 31, 2014 | $378.19M | Oct 27, 2014 |
| FY2014 | Feb 28, 2014 | $327.77M | Oct 27, 2014 |
| FY2014 | Nov 30, 2013 | $339.56M | Oct 27, 2014 |
| FY2014 | Aug 31, 2013 | $327.26M | Oct 27, 2014 |
| FY2014 | May 31, 2013 | $344.21M | Oct 27, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $311.83M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $301.01M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $295.04M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $265.39M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $243.16M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $217.19M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $292.65M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $283.28M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | $260.37M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $403.40M | Oct 29, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $92.75M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $85.75M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $46.56M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $15.69M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $38.08M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $723.0K | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | ($249.15M) | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | ($21.65M) | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | ($66.21M) | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | ($105.17M) | Oct 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $133.47M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $121.59M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $83.92M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $30.66M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $51.11M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $24.18M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $47.52M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $50.21M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | ($84.85M) | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | ($100.22M) | Oct 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $14.50M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $12.40M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $9.00M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $7.30M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $7.40M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $7.30M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $9.30M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $8.70M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | $8.90M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $18.30M | Oct 29, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $166.92M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $168.57M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $205.06M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $216.87M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $175.28M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $180.51M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $209.23M | Oct 25, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $111.28M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $81.32M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $77.60M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $51.74M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $54.18M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | ($3.16M) | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $53.85M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $106.09M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | $88.50M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $117.70M | Oct 29, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $827.87M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $777.33M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $762.60M | Oct 21, 2024 |
| FY2023 | Aug 31, 2022 | $757.31M | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $820.25M | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $824.29M | Oct 25, 2021 |
| FY2020 | Aug 31, 2019 | $1.12B | Oct 26, 2020 |
| FY2019 | Aug 31, 2018 | $1.49B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $1.52B | Oct 29, 2018 |
| FY2017 | Aug 31, 2016 | $1.44B | Oct 26, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $394.17M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $385.35M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $435.98M | Oct 21, 2024 |
| FY2023 | Aug 31, 2022 | $438.70M | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $408.05M | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $465.07M | Oct 25, 2021 |
| FY2020 | Aug 31, 2019 | $823.10M | Oct 26, 2020 |
| FY2019 | Aug 31, 2018 | $926.51M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $1.02B | Oct 29, 2018 |
| FY2017 | Aug 31, 2016 | $917.71M | Oct 26, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $289.79M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $269.60M | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | $266.49M | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | $257.95M | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | $277.59M | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | $281.15M | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | $260.42M | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | $280.13M | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | $272.42M | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | $519.28M | Oct 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $284.10M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $261.87M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $1.01B | Oct 21, 2024 |
| FY2023 | Aug 31, 2022 | $966.75M | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $953.34M | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $917.67M | Oct 25, 2021 |
| FY2020 | Aug 31, 2019 | $915.47M | Oct 26, 2020 |
| FY2019 | Aug 31, 2018 | $1.17B | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $1.19B | Oct 29, 2018 |
| FY2017 | Aug 31, 2016 | $1.26B | Oct 26, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $151.56M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $167.09M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $154.42M | Oct 21, 2024 |
| FY2023 | Aug 31, 2022 | $120.70M | Oct 20, 2023 |
| FY2022 | Aug 31, 2021 | $140.35M | Oct 25, 2022 |
| FY2021 | Aug 31, 2020 | $152.17M | Oct 25, 2021 |
| FY2021 | Aug 31, 2019 | $211.15M | Oct 25, 2021 |
| FY2021 | Aug 31, 2018 | $250.49M | Oct 25, 2021 |
| FY2020 | Aug 31, 2017 | $229.57M | Oct 26, 2020 |
| FY2019 | Aug 31, 2016 | $179.60M | Oct 29, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $190.00M | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | $195.00M | Oct 17, 2025 |
| FY2024 | Aug 31, 2023 | $214.75M | Oct 21, 2024 |
| FY2023 | Aug 31, 2022 | $204.00M | Oct 20, 2023 |
| FY2020 | Aug 31, 2020 | $255.00M | Oct 26, 2020 |
| FY2020 | Aug 31, 2019 | $462.56M | Oct 26, 2020 |
| FY2019 | Aug 31, 2018 | $535.06M | Oct 29, 2019 |
| FY2018 | Aug 31, 2017 | $565.06M | Oct 29, 2018 |
| FY2017 | Aug 31, 2016 | $584.31M | Oct 26, 2017 |
| FY2015 | Aug 31, 2015 | $588.06M | Oct 28, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 1 | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | 1 | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | 0 | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | 0 | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | 0 | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | 0 | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | (4) | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | 0 | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | (1) | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | (1) | Oct 29, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | 1 | Oct 17, 2025 |
| FY2025 | Aug 31, 2024 | 1 | Oct 17, 2025 |
| FY2025 | Aug 31, 2023 | 0 | Oct 17, 2025 |
| FY2024 | Aug 31, 2022 | 0 | Oct 21, 2024 |
| FY2023 | Aug 31, 2021 | 0 | Oct 20, 2023 |
| FY2022 | Aug 31, 2020 | 0 | Oct 25, 2022 |
| FY2021 | Aug 31, 2019 | (4) | Oct 25, 2021 |
| FY2020 | Aug 31, 2018 | 0 | Oct 26, 2020 |
| FY2019 | Aug 31, 2017 | (1) | Oct 29, 2019 |
| FY2018 | Aug 31, 2016 | (1) | Oct 29, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Aug 31, 2011 | 68.66M | Oct 28, 2011 |
| FY2011 | Aug 31, 2010 | 68.06M | Oct 28, 2011 |